1GI Motility Program, Division of Gastroenterology, Department of Medicine, Cedars-Sinai, Los Angeles, California, USA
2Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
3Beth Israel Deaconess Medical Center, Department of Medicine, Boston, Massachusetts, USA
4New Mexico VA Health Care System, Division of Gastroenterology and Hepatology, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA
5Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA
6Division of Gastroenterology and Hepatology, Department of Medicine, Augusta University, Augusta, Georgia, USA
7Laboratorio de Hígado, Páncreas y Motilidad (HIPAM)-Unit of Research in Experimental Medicine, Faculty of Medicine-Universidad Nacional Autónoma de México (UNAM), Department of Medicine, Mexico City, Mexico
8GI Motility and Neurogastroenteroly Unit, Department of Gastroenterology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
9Connecticut Gastroenterology Institute, Department of Medicine, Bristol Hospital, Bristol, Connecticut, USA
Correspondence: Ali Rezaie, MD, MSc, FRCP(C), Assistant Professor, Assistant Director, GI Motility Program, Cedars-Sinai Medical Center, 8730 Alden Drive, Suite 2E, Los Angeles, California 90048, USA. E-mail: [email protected]
SUPPLEMENTARY MATERIAL accompanies this paper at https://links.lww.com/AJG/A469
Received 01 August 2016; accepted 02 January 2017
Guarantor of the article: Ali Rezaie, MD, FRCPC.
Specific author contributions: Conceived and planned the consensus group and designed the pre-meeting survey questions: A.R. and M.P.; responded to the pre-meeting survey questions, and all authors participated in the consensus group meeting: M.B., A.L., H.L., R.M., S.R., M.S., M.V., and S.Z.; voted on the consensus statements: M.B., A.L., H.L., R.M., S.R., M.S., M.V., M.P. and S.Z.; drafted the manuscript: A.R. and M.P.; and reviewed and edited the manuscript: M.B., A.L, H.L., R.M., S.R., M.S., M.V., and S.Z.; all the authors approved the final draft submitted.
Financial support: The consensus group meeting was supported in part by Commonwealth Laboratories (Commonwealth Laboratories, Boston, MA). Commonwealth Laboratories had no role in the election of committee members, determination of the topics of presentations/discussion, drafting or approving these consensus statements.
Potential competing interests: Ali Rezaie reports support from the following sources for teaching, research, and consultation, outside the submitted work: Commonwealth Laboratories, Actavis, and Salix Pharmaceuticals. Henry Lin reports related intellectual property rights. Michelle Buresi, Richard McCallum, Salam Zakko and Miguel Valdovinos report no conflicts of interest. Anthony Lembo reports receiving fees for serving on advisory boards from Allergen, Furiex Pharmaceuticals, Prometheus Laboratories, Salix Pharmaceuticals, Valeant Pharmaceuticals, Forest Laboratories, Alkermes, AstraZeneca, and Ironwood Pharmaceuticals. Satish Rao reports support from the following sources for teaching, research, and consultation, outside the submitted work: Forest Laboratories, Hollister, Ironwood Pharmaceuticals, Sucampo Pharmaceuticals, In Control Medical, Vibrant, American Medical Systems, Sun Sweet Corporation, Synergy Pharmaceuticals, Salix Pharmaceuticals, and Ventrus Laboratories. Max Schmulson has received grant supports from Alfa Wasserman and Nestle. He has served on the Advisory Board of Alfa Wasserman, is currently a consultant for Commonwealth Laboratories Inc and Commonwealth Diagnostics International Inc and in the past has been a consultant for Almirall, Janssen, Nestle, Novartis, Procter and Gamble, Senosiain and Takeda Mexico. Has been a speaker for Alfa Wasserman, Commonwealth Diagnostics International Inc, Janssen, Mayoly-Spindler and Takeda Mexico. Mark Pimentel is a consultant for Valeant Pharmaceuticals, Commonwealth Laboratories, Synthetic Biologics, Micropharma, and Naia Pharmaceuticals, and is on the advisory boards for Valeant Pharmaceuticals and Commonwealth Laboratories. Cedars-Sinai has a licensing agreement with Valeant Pharmaceuticals International Inc., Commonwealth Laboratories, and Synthetic Biologics.
